The US Food and Drug Administration (FDA) has approved Neffy, a novel epinephrine nasal spray, for the treatment of emergency allergic reactions, including anaphylaxis.

This marks a significant advancement in the management of severe allergies, offering an alternative to traditional injectable epinephrine.

Key Features of Neffy include:

• It is approved for adults and children who weigh at least 66 lbs.

• The FDA fast-tracked the approval based on studies showing comparable levels of epinephrine in the blood after using the spray or injection.

• Neffy is administered with a single spray in one nostril, with a second dose recommended if symptoms don't improve.

• Possible side effects include throat irritation, tingling in the nose, and headaches.

• The FDA's announcement emphasizes the crucial need addressed by neffy, as individuals, particularly children, often delay seeking emergency treatment due to a fear of injections.

Click here to read more